Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
2.290
+0.040 (1.78%)
At close: Nov 26, 2025, 4:00 PM EST
2.286
-0.004 (-0.16%)
After-hours: Nov 26, 2025, 7:06 PM EST

Neumora Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
63.2962.5445.4831.1224.558.39
Upgrade
Research & Development
177.31200.93142.7291.7555.7817.31
Upgrade
Operating Expenses
240.6263.46188.19122.8780.3225.71
Upgrade
Operating Income
-240.6-263.46-188.19-122.87-80.32-25.71
Upgrade
Interest & Investment Income
11.119.9316.614.56--
Upgrade
Other Non Operating Income (Expenses)
-0.48-0.08-0.170.410.01-0.08
Upgrade
EBT Excluding Unusual Items
-231.17-243.61-171.75-117.9-80.31-25.79
Upgrade
Merger & Restructuring Charges
------0.7
Upgrade
Other Unusual Items
------3.28
Upgrade
Pretax Income
-236.17-243.61-235.66-130.9-237.31-99.27
Upgrade
Income Tax Expense
0.130.180.27---
Upgrade
Net Income
-236.3-243.79-235.93-130.9-237.31-99.27
Upgrade
Net Income to Common
-236.3-243.79-235.93-130.9-237.31-99.27
Upgrade
Shares Outstanding (Basic)
16115965272213
Upgrade
Shares Outstanding (Diluted)
16115965272213
Upgrade
Shares Change (YoY)
2.49%145.12%138.99%24.25%68.46%-
Upgrade
EPS (Basic)
-1.46-1.53-3.63-4.81-10.84-7.64
Upgrade
EPS (Diluted)
-1.46-1.53-3.63-4.81-10.84-7.64
Upgrade
Free Cash Flow
-208.07-182.94-163.4-115.41-76.24-28.06
Upgrade
Free Cash Flow Per Share
-1.29-1.15-2.51-4.24-3.48-2.16
Upgrade
EBITDA
-240.24-262.83-187.53-122.28-79.79-25.6
Upgrade
D&A For EBITDA
0.360.630.670.590.540.11
Upgrade
EBIT
-240.6-263.46-188.19-122.87-80.32-25.71
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q